South Korea · Delayed Price · Currency is KRW Ingenia Therapeutics Company Description
Ingenia Therapeutics Inc. operates as a clinical-stage antibody biopharmaceutical company that discovers and develops biopharmaceutical candidates based on microvascular protection and recovery technology in the United States and South Korea.
The company engages in the discovery and development of advanced therapeutics for patients afflicted by inflamed and leaky blood vessels.
Its products for the treatment of ophthalmic diseases include IGT-427 for retinal diseases and IGT-302 for Glaucoma; and its systemic products include IGT-303 for CKD; IGT-532 for cancer; and other multiple candidates.
Additionally, the company's technology includes a Tie2 receptor-activating antibody platform that repairs damaged microvessels.
Ingenia Therapeutics Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
| Country | United States |
| Founded | 2018 |
| Industry | Commercial Physical and Biological Research |
| Employees | 20 |
| CEO | Sangyeul Han |
Contact Details
Address: 490 Arsenal Way Watertown, Massachusetts 02472 United States | |
| Phone | 617-440-2500 |
| Website | ingeniatx.com |
Stock Details
| Ticker Symbol | 950260 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Sangyeul Han | Chief Executive Officer |
| Sung-cheol Park | Chief Financial Officer |
| Chris Chung | Head of Investor Relations |